Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs NEOD 001 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- Acronyms OLE
- Sponsors Prothena
- 23 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 23 Oct 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 10 Aug 2016 Status changed from not yet recruiting to active, no longer recruiting.